Synopsis
Gout is a physical conditions that affects the patient’s ability to move, often also termed as unwalkable disease, and it has been around for centuries.
The global Gout Therapeutics market size is expected to reach US$ 10260 million by 2029, growing at a CAGR of 13.0% from 2023 to 2029. The market is mainly driven by the significant applications of Gout Therapeutics in various end use industries. The expanding demands from the Acute Gout and Chronic Gout, are propelling Gout Therapeutics market. NSAIDs, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Corticosteroids segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Gout Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Gout Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Gout Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Gout Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Gout Therapeutics covered in this report include Takeda Pharmaceutical Company, Novartis, AstraZeneca, GlaxoSmithKline, Merck and Regeneron Pharmaceuticals, etc.
The global Gout Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Takeda Pharmaceutical Company
Novartis
AstraZeneca
GlaxoSmithKline
Merck
Regeneron Pharmaceuticals
Global Gout Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Gout Therapeutics market, Segment by Type:
NSAIDs
Corticosteroids
Colchicine
Urate-Lowering Agents
Global Gout Therapeutics market, by Application
Acute Gout
Chronic Gout
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Gout Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index
1 Market Overview of Gout Therapeutics
1.1 Gout Therapeutics Market Overview
1.1.1 Gout Therapeutics Product Scope
1.1.2 Gout Therapeutics Market Status and Outlook
1.2 Global Gout Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Gout Therapeutics Market Size by Region (2018-2029)
1.4 Global Gout Therapeutics Historic Market Size by Region (2018-2023)
1.5 Global Gout Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Gout Therapeutics Market Size (2018-2029)
1.6.1 North America Gout Therapeutics Market Size (2018-2029)
1.6.2 Europe Gout Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific Gout Therapeutics Market Size (2018-2029)
1.6.4 Latin America Gout Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa Gout Therapeutics Market Size (2018-2029)
2 Gout Therapeutics Market by Type
2.1 Introduction
2.1.1 NSAIDs
2.1.2 Corticosteroids
2.1.3 Colchicine
2.1.4 Urate-Lowering Agents
2.2 Global Gout Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Gout Therapeutics Historic Market Size by Type (2018-2023)
2.2.2 Global Gout Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Gout Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Gout Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Gout Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Gout Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Gout Therapeutics Revenue Breakdown by Type (2018-2029)
3 Gout Therapeutics Market Overview by Application
3.1 Introduction
3.1.1 Acute Gout
3.1.2 Chronic Gout
3.2 Global Gout Therapeutics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Gout Therapeutics Historic Market Size by Application (2018-2023)
3.2.2 Global Gout Therapeutics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Gout Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Gout Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Gout Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Gout Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Gout Therapeutics Revenue Breakdown by Application (2018-2029)
4 Gout Therapeutics Competition Analysis by Players
4.1 Global Gout Therapeutics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Gout Therapeutics as of 2022)
4.3 Date of Key Players Enter into Gout Therapeutics Market
4.4 Global Top Players Gout Therapeutics Headquarters and Area Served
4.5 Key Players Gout Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Gout Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Takeda Pharmaceutical Company
5.1.1 Takeda Pharmaceutical Company Profile
5.1.2 Takeda Pharmaceutical Company Main Business
5.1.3 Takeda Pharmaceutical Company Gout Therapeutics Products, Services and Solutions
5.1.4 Takeda Pharmaceutical Company Gout Therapeutics Revenue (US$ Million) & (2018-2023)
5.1.5 Takeda Pharmaceutical Company Recent Developments
5.2 Novartis
5.2.1 Novartis Profile
5.2.2 Novartis Main Business
5.2.3 Novartis Gout Therapeutics Products, Services and Solutions
5.2.4 Novartis Gout Therapeutics Revenue (US$ Million) & (2018-2023)
5.2.5 Novartis Recent Developments
5.3 AstraZeneca
5.3.1 AstraZeneca Profile
5.3.2 AstraZeneca Main Business
5.3.3 AstraZeneca Gout Therapeutics Products, Services and Solutions
5.3.4 AstraZeneca Gout Therapeutics Revenue (US$ Million) & (2018-2023)
5.3.5 GlaxoSmithKline Recent Developments
5.4 GlaxoSmithKline
5.4.1 GlaxoSmithKline Profile
5.4.2 GlaxoSmithKline Main Business
5.4.3 GlaxoSmithKline Gout Therapeutics Products, Services and Solutions
5.4.4 GlaxoSmithKline Gout Therapeutics Revenue (US$ Million) & (2018-2023)
5.4.5 GlaxoSmithKline Recent Developments
5.5 Merck
5.5.1 Merck Profile
5.5.2 Merck Main Business
5.5.3 Merck Gout Therapeutics Products, Services and Solutions
5.5.4 Merck Gout Therapeutics Revenue (US$ Million) & (2018-2023)
5.5.5 Merck Recent Developments
5.6 Regeneron Pharmaceuticals
5.6.1 Regeneron Pharmaceuticals Profile
5.6.2 Regeneron Pharmaceuticals Main Business
5.6.3 Regeneron Pharmaceuticals Gout Therapeutics Products, Services and Solutions
5.6.4 Regeneron Pharmaceuticals Gout Therapeutics Revenue (US$ Million) & (2018-2023)
5.6.5 Regeneron Pharmaceuticals Recent Developments
6 North America
6.1 North America Gout Therapeutics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Gout Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Gout Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Gout Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Gout Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Gout Therapeutics Market Dynamics
11.1 Gout Therapeutics Industry Trends
11.2 Gout Therapeutics Market Drivers
11.3 Gout Therapeutics Market Challenges
11.4 Gout Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List